Melinta Therapeutics
Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTI
February 27, 2018 16:05 ET | Melinta Therapeutics
- VABOMERE demonstrated a greater numerical overall success rate vs piperacillin-tazobactam - VABOMERE safety profile comparable to piperacillin-tazobactam NEW HAVEN, Conn., Feb. 27, 2018 (GLOBE...
Melinta Therapeutics
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
November 29, 2017 07:00 ET | Melinta Therapeutics
- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV® - - Peak sales potential of the...